Baidu
map

Neurology : Neurofascin-155免疫球蛋白亚型,临床病理关联和神经结局

2021-10-16 Freeman MedSci原创

NF155-IgG4(而不是IgM或IgG)患者具有独特的临床-电诊断特征

Neurofascin-155(NF155)自身抗体是最常见的结节和副结节抗体之一,占所有慢性脱髓鞘多发性神经病(CIDP)病例的4%至18%。尽管这些抗体在临床实践中的应用越来越多,但评估长期结果和组织病理学特征的研究是有限的。

藉此,梅奥诊所的Shahar Shelly等人, 探究了一个大型脱髓鞘神经病队列中NF155自身抗体的频率。并评估表型和组织病理学特异性,以及NF155-IgG4血清阳性、NF155泛IgG和NF155-IgM血清阳性病例之间的结果差异。最后,还比较了NF155-IgG4阳性病例与髓鞘相关糖蛋白(MAG)-IgM和Contactin-1 IgG相关脱髓鞘神经病的表型差异和结果。

方法。在这项研究中,对在梅奥诊所就诊的神经病患者血清进行了NF155-IgG4、NF155-IgG和NF155-IgM自身抗体的检测。对所有血清阳性病例的人口学和临床数据进行了回顾。

他们发现了32名NF155患者(25名NF155-IgG阳性[20名NF155-IgG4阳性],7名NF155-IgM血清阳性)。NF155-IgG4血清阳性患者临床上表现为远端肌无力多于近端肌无力,感觉症状阳性(刺痛、不对称性麻痹、神经性疼痛)和步态共济失调。许多人出现颅神经受累(11/20,55%)和乳头水肿(4/12,33%)。

诊断测试(EDX)显示脱髓鞘多发性神经病(19/20,95%)。45%的患者出现自主神经受累(9人,中位CASS评分3.5,范围1-7)。NF155-IgG4患者(n=11)的神经活检显示有分组的节段性脱髓鞘(50%),髓鞘重排(45%)和副节肿胀(50%)。大多数患者需要二线和三线的免疫抑制,但有良好的长期疗效(n=18)。在14名有2年以上连续EDX的患者中,除一人外,所有患者在治疗后都有改善。

NF155-IgG阳性的NF155-IgG4阴性(NF155-IgG阳性)和NF155-IgM阳性患者在表型上与NF155-IgG4血清阳性患者不同。

与MAG-IgM神经病相比,NF155-IgG4阳性患者的感觉共济失调、神经性疼痛、小脑功能障碍和根/神经丛MRI异常明显更常见。

与NF155-IgG4阳性病例相比,慢性免疫感觉多发性神经病(CISP)/CISP-plus表型在Contactin-1神经病中更常见。

与MAG-IgM血清阳性病例相比,NF155-IgG4阳性病例对免疫治疗反应良好,与接触素-1 IgG相比,远端获得性脱髓鞘对称性神经病(P<0.001),长期临床疗效更好(P=0.04)。

这个研究的重要意义在于发现了NF155-IgG4患者的长期随访和临床结果。NF155-IgG4(而不是IgM或IgG)患者具有独特的临床-电诊断特征。并证明NF155-IgG4阳性患者,与经典的CIDP不同,在发病时常见神经性疼痛和自律性失调。长期的结果是有利的。



原文出处:
Shelly S, Klein C, Dyck PJB, et al. Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. Published online October 11, 2021:10.1212/WNL.0000000000012932. doi:10.1212/WNL.0000000000012932

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-12-05 xzw113
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2022-02-26 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2022-08-09 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2022-06-18 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2022-06-18 yinhl1978
  7. [GetPortalCommentsPageByObjectIdResponse(id=2035265, encodeId=b0c72035265fb, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Dec 05 15:34:11 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058001, encodeId=e61920580014c, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Feb 26 00:34:11 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939256, encodeId=1a101939256b7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Aug 09 06:34:11 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774000, encodeId=2c4a1e74000d3, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Jun 18 02:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797490, encodeId=c0d41e9749000, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 29 14:34:11 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001522, encodeId=9433200152229, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jun 18 18:34:11 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283931, encodeId=948412839319e, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Mon Oct 18 10:34:11 CST 2021, time=2021-10-18, status=1, ipAttribution=)]

相关资讯

Neurology-LGI1-抗体脑炎者,行免疫治疗仍会出现慢性癫痫

LGI1-抗体脑炎者,行免疫治疗仍会出现慢性癫痫

Annals of Neurology:认知障碍,是NMDAR脑炎长期发病的主要因素

认知障碍是导致NMDAR脑炎长期发病的主要因素

JAMA Neuro:“万金油”免疫治疗真的万能!来看看NMDAR抗体脑炎IVIG的疗效

影响NMDARE患者功能结果和复发的因素是不同的,但首次发病使用IVIG确实可以改善患者预后。

Ann Neurol:部分新冠疫苗有引起脑炎风险,但......还是建议接种

接种ChAdOx1 nCoV-19疫苗接种后并发脑炎的情况仍然非常罕见,但需要得到充分的诊断和治疗,而且接种疫苗的好处大于风险。

伴有胼胝体压部可逆性病变的临床症状轻微的脑炎/脑病一例

患者女,26岁。主因“反复发热12d”于2017-03-31入院。入院前12d不明原因出现发热,最高体温39.4℃,伴畏寒、寒战,伴尿频、尿急、尿痛,无咳嗽咳痰,无肢体乏力,间断发热,自行口服布洛芬后

Neurology :新冠之后,自身免疫性脑炎发病情况如何?

他们在2020年的COVID-19经验中偶尔遇到了AE的病例。

拓展阅读

台湾首现2例日本脑炎病例1人死亡

近日,“台湾首现2例日本脑炎病例1人死亡”的话题冲上热搜,引发网友热议。

Neurology病例:阿特珠单抗诱发的脑炎相关的双侧丘脑病变:尸检结果的后续报告

阿特珠单抗诱发的脑炎相关的双侧丘脑病变:尸检结果的后续报告

儿童新冠病毒感染后,高烧抽搐,重点关注什么?

从全球来看,儿童感染新冠病毒后的风险是极低的,重症和死亡率都是非常低的。然而,对于婴幼儿,其并发症不容忽视。

JNNP : 成人MOG抗体相关性脑炎临床症状

成人MOGAE可分为三种表型,皮质脑炎、LE和ADEM,它们具有不同的临床特征、结果和复发率。

DWI 高信号除了脑梗死,还有哪些是你知道的!!

神经科的一系列疾病中,DWI 高信号最常见的自然是缺血性脑卒中的急性期,但是当你见到主要累及皮层、且不按大脑血管供血区分布的弥漫性 DWI 高信号时,往往需要想到神经科最可怕的疾病之一。

脑炎、脑膜炎重症管理的新进展

在成人中进行的多中心研究提高了目前对重症脑膜炎和脑炎的流行病学和疾病预后认识。

Baidu
map
Baidu
map
Baidu
map